Milestone payments are an important risk-sharing component in today’s biopharma deal-making toolbox. As it’s a topic I’ve explored in the past (here, here), it’s an opportune time to revisit the stats for how they have performed recently.
These contingent value transfers (a.k.a. biobucks) help to bridge the gap in deal expectations, and provide a future reward if a deal withstands the battering of project attrition and advances successfully towards and beyond product approval. Of the $8.4B in VC-backed M&A “value” in 2014, $3.3B was in the form of these biobucks; upfront payments have only been~50% of the total value for most of the last few years.
Hey, check out all the research scientist jobs. Post your resume today!
